OB
OBIO.US Orchestra BioMed Holdings Inc.
- Market cap
- USD 560M
- P/E
- -
- P/B
- 73.02x
- ROE
- -449.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OBIO.US undervalued?
Graham numberThe Graham number of Orchestra BioMed Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orchestra BioMed Holdings Inc. fundamental analysis
No fundamental analysis for Orchestra BioMed Holdings Inc. yet.
Orchestra BioMed Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of c…
Full company profileOrchestra BioMed Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Orchestra BioMed Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 5.70M | -782K | 3.53M | 2.76M | 2.64M | 33.5M | 385K |
| Gross Profit | 5.56M | -981K | 3.21M | 2.57M | 2.43M | 33.3M | 192K |
| Operating Income | -18.8M | -21.8M | -32.7M | -51.5M | -64.3M | -51.8M | -90.3M |
| EBITDA | -18.6M | -21.9M | -33.4M | -48.8M | -60.7M | -51.2M | -79.5M |
| Net Income | -21.4M | -23.0M | -33.6M | -49.1M | -61.0M | -52.7M | -84.3M |
| EPS | -1.04 | -1.13 | -1.32 | -1.48 | -1.66 | -1.10 | 0.00 |
| Balance Sheet | |||||||
| Total Assets | 38.1M | 13.5M | 95.6M | 95.2M | 76.2M | 115M | 108M |
| Total Liabilities | 86.6M | 84.8M | 43.0M | 27.2M | 43.2M | 51.5M | 89.0M |
| Shareholders' Equity | -48.5M | -71.2M | 52.5M | 68.0M | 33.0M | 63.4M | 18.7M |
| Cash & Short-term Investments | 35.8M | 10.9M | 83.8M | 87.6M | 66.8M | 107M | 102M |
| Total Debt | 9.46M | 5.67M | 11.9M | 1.69M | 16.5M | 16.0M | 73.5M |
| Cash Flow | |||||||
| Operating Cash Flow | -26.2M | -19.4M | -29.3M | -46.1M | -50.6M | -49.0M | -81.4M |
| Capital Expenditure | 539K | 274K | 591K | 78.0K | 289K | 489K | 1.11M |
| Free Cash Flow | -26.7M | -19.7M | -29.9M | -46.2M | -50.8M | -49.5M | -82.5M |
| Ratios | |||||||
| ROE | - | - | -64.0% | -72.2% | -185.2% | -83.2% | -449.5% |
| ROA | -56.1% | -170.1% | -35.2% | -51.6% | -80.1% | -45.9% | -78.2% |
| Net Profit Margin | -374.5% | - | -951.3% | -1,779.7% | -2,313.3% | -157.4% | -21,867.1% |
| Debt to Equity | - | - | 0.23x | 0.02x | 0.50x | 0.25x | 3.92x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Orchestra BioMed Holdings Inc. dividends
Orchestra BioMed Holdings Inc. has not paid dividends in the last 6 fiscal years.
Who owns Orchestra BioMed Holdings Inc.
- Insiders 18.68%
- Institutions 38.73%
- Public & others 42.59%
- Shares outstanding 78.7M
- Free float 47.9M
Top funds holding OBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.47M | 2.39% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 960K | 1.56% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 429K | 0.70% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 379K | 0.62% | -0.38% | Oct 2026 |
| UBS(Lux)EF Sust Hlth Trnsfm $ P | 362K | 0.59% | +5.12% | Jul 2026 |
| UBS (Lux) EF Biotech (USD) P-acc | 341K | 0.56% | +14.63% | Jul 2026 |
| Vanguard Russell 2000 ETF | 232K | 0.38% | +1.15% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 232K | 0.38% | +0.24% | Oct 2026 |
| BlackRock Health Sciences Opps Inv A | 206K | 0.34% | 0.00% | Sep 2026 |
| Simplify Propel Opportunities ETF | 195K | 0.32% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 191K | 0.31% | +41.71% | Sep 2026 |
| iShares Micro-Cap ETF | 122K | 0.20% | 0.00% | Oct 2026 |
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 101K | 0.16% | 0.00% | Jul 2026 |
| Schwab Small Cap Index | 97.3K | 0.16% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 77.3K | 0.13% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 74.5K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 72.9K | 0.12% | -0.05% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 71.5K | 0.12% | 0.00% | Oct 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 70.5K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 64.7K | 0.11% | 0.00% | Sep 2026 |
Top institutions holding OBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 9.56M | 15.55% | +15.05% | Jun 2026 |
| Perceptive Advisors LLC | 5.04M | 8.20% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.51M | 4.09% | +294.89% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.02M | 3.29% | -8.23% | Jun 2026 |
| Geode Capital Management, LLC | 1.01M | 1.64% | +107.61% | Jun 2026 |
| Alyeska Investment Group, L.P. | 1.00M | 1.63% | 0.00% | Jun 2026 |
| Propel Bio Management LLC | 897K | 1.46% | 0.00% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 642K | 1.05% | 0.00% | Jun 2026 |
| State Street Corp | 516K | 0.84% | +204.62% | Jun 2026 |
| Rice Hall James & Associates, LLC | 424K | 0.69% | +2,131.46% | Jun 2026 |
| Charles Schwab Investment Management Inc | 350K | 0.57% | +31.66% | Jun 2026 |
| Northern Trust Corp | 344K | 0.56% | +190.55% | Jun 2026 |
| UBS Group AG | 326K | 0.53% | +547.53% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 292K | 0.48% | +24.25% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 275K | 0.45% | 0.00% | Jun 2026 |
| Knott David M Jr | 254K | 0.41% | 0.00% | Jun 2026 |
| Flat Footed LLC | 251K | 0.41% | 0.00% | Jun 2026 |
| Simplify Asset Management Inc. | 219K | 0.36% | 0.00% | Sep 2026 |
| The Goldman Sachs Group Inc | 180K | 0.29% | +15.69% | Jun 2026 |
| Dafna Capital Management LLC | 127K | 0.21% | 0.00% | Jun 2026 |
Orchestra BioMed Holdings Inc. company profile
- Company name
- Orchestra BioMed Holdings Inc.
- Ticker
- OBIO.US
- Exchange
- USA Stocks
- Listed since
- Aug 4, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 86
- Fiscal year end
- December
- Address
- 150 Union Square Drive, New Hope, PA, United States, 18938
- Phone
- 215 862 5797
- Website
- orchestrabiomed.com
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Orchestra BioMed Holdings Inc. management
10- Mr. David P. HochmanFounder, Chairman of the Board of Directors & CEO · born 1975
- Mr. Darren R. ShermanFounder, President, COO & Director · born 1971
- Mr. Andrew Lawrence Taylor M.B.A.Chief Financial Officer · born 1971
- Mr. William Reed LittleExecutive Vice President of Corporate Development & Strategy · born 1971
- Ms. Lisa DanielsVice President of Human Resources
- Dr. Yuval Hay Mika D.Sc, Ph.D.GM & CTO of Bioelectronic Therapies · born 1959
- Dr. Hans-Peter Stoll M.D., Ph.D.Senior VP & Medical Director
- Dr. Avraham Matityahu Fischer M.D.Senior Vice President of Medical Affairs & Innovation · born 1956
- Mr. Bob LaughnerSenior Vice President of Regulatory & Quality
- Mr. Juan LorenzoSenior Vice President of Product Development